Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Senior writer
Maryland, USA
16+ years of experience
Scrip
By Joseph Haas 17 Jan 2022
Licensing deals and partnerships carried the day during another hectic J.P. Morgan Healthcare Conference. Pfizer racked up its third deal of the week in a cancer collaboration with Dren Bio.
Scrip
By Joseph Haas 01 Oct 2021
Merck/Ridgeback’s ribonucleoside analog shows nearly 50% reduction of risk for hospitalization or death in Phase III study. Firms will seek EUA in US; a contract is in place for 1.7 million courses of therapy.
Scrip
By Joseph Haas 27 Nov 2020
With efficacy data in hand, Gilead wants to balance economic sustainability with broad availability of remdesivir for COVID-19 patients. The firm did not alter guidance on Q1 earnings call.
Topic Coronavirus
Scrip
By Joseph Haas 27 Nov 2020
The pharma and the Google spinout focused on aging are adding $1bn in funding to their 2014 collaboration, which has yielded more than two dozen preclinical candidates so far.
Topic Alzheimer's Disease
Pink Sheet
By Joseph Haas 29 Oct 2020
EUA request for COVID-19 vaccine is unlikely before late November; the CEO’s frequent comments that the timetable isn’t politically motivated are unusual to say the least
Scrip
By Joseph Haas 03 Jun 2020
Remdesivir shows ability to yield clinical improvement in moderately ill COVID-19 patients, but data are called ‘modest’ and shorter therapy duration showed better results than longer.
Topic Coronavirus Clinical Trials
Scrip
By Joseph Haas 01 May 2020
With efficacy data in hand, Gilead wants to balance economic sustainability with broad availability of remdesivir for COVID-19 patients. The firm did not alter guidance on Q1 earnings call.
Scrip
By Joseph Haas 20 Apr 2020
Big pharma stocks, with few exceptions, saw big declines in valuation in the quarter amid the COVID-19 stock market rollercoaster, but pharma outperformed the S&P 500, showing the industry's resiliency in a global health crisis.
Scrip
By Joseph Haas 06 Apr 2020
The companies are combining their technologies to seek neutralizing antibody therapeutics that could prevent or treat COVID-19, building on their previous partnership in monitoring minimal residual disease in blood cancers.
Topic Coronavirus
Scrip
By Joseph Haas 27 Mar 2020
AlloVir/Baylor, Soligenix/Hawaii and CEL-SCI/Georgia ink coronavirus collaborations, but deal-making continues in other areas as well, including Asklepios/UNC teaming on a gene therapy for Angelman syndrome and DeMelle licensing a targeted pancreatic cancer drug from Moffitt, among others.
Topic Coronavirus Medtech
Scrip
By Joseph Haas 15 Jan 2020
Biktarvy’s powerful sales growth and the potential of a first-in-class capsid inhibitor in both prevention and heavily treatment-experienced patients are key to Gilead’s plan for staying on top in HIV.
Topic Business Strategies Infectious Diseases Life Cycle Management
Datamonitor Healthcare
By Joseph Haas 01 Nov 2019
Non-alcoholic steatohepatitis (NASH) is poised to become an even greater epidemic and pharma companies of all sizes are competing to be the first to bring a NASH drug to market. Listen to an in-depth discussion about new and repurposed drug exploration treat NASH, as well as deal making, licensing and partnerships activity for the area.
Topic Cell & Gene Therapy Drug Development Landscape Approvals
Scrip
By Joseph Haas 11 Sep 2019
The Medicines Co. unveiled Phase III safety data for inclisiran showing safety and tolerability comparable to placebo and efficacy in line with the PCSK9 inhibitor class – which should be the reassurance it needs for the oral agent.
Scrip
By Joseph Haas 03 Jul 2019
Looking back at the second quarter, PharmaVitae analysts have selected 10 biopharma companies with market caps under $3bn they think are primed for acquisition – and the likely candidates for a buy-out.
Scrip
By Joseph Haas 02 Jul 2019
ODYSSEY Outcomes data added to US label for Praluent; update includes claim for reduced cardiovascular incident risk and trial data indicating an all-cause mortality benefit.
Scrip
22 Jul 2022
Scrip
21 Jul 2022
Scrip
20 Jul 2022
Scrip
19 Jul 2022
In Vivo
11 Jul 2022
Scrip
05 Jul 2022
Scrip
01 Jul 2022
Scrip
28 Jun 2022
Scrip
28 Jun 2022
Scrip
24 Jun 2022
Scrip
24 Jun 2022
Scrip
23 Jun 2022
Scrip
22 Jun 2022
Scrip
17 Jun 2022
Scrip
16 Jun 2022
